A carregar...
Dose–response of an extrafine dry powder inhaler formulation of glycopyrronium bromide: randomized, double-blind, placebo-controlled, dose-ranging study (GlycoNEXT)
INTRODUCTION: An extrafine formulation of the long-acting muscarinic antagonist, glycopyrronium bromide (GB), has been developed for delivery via the NEXThaler dry powder inhaler (DPI). This study assessed the bronchodilator efficacy and safety of different doses of this formulation in patients with...
Na minha lista:
| Publicado no: | Int J Chron Obstruct Pulmon Dis |
|---|---|
| Main Authors: | , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Dove Medical Press
2018
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5973313/ https://ncbi.nlm.nih.gov/pubmed/29872288 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/COPD.S168493 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|